Mu ntangiriro za Gicurasi 2023, TAGMe ADN Methylation Detection Kit (qPCR) ya Kanseri ya Urothelial yigenga yakozwe na Shanghai Epiprobe Biotechnology Co., Ltd, yabonye “Breakthrough Device Designation” muri Amerika FDA.
Porogaramu yo muri Amerika FDA Breakthrough Devices igamije kwemeza kuzamura ibicuruzwa by’abakora ku isoko mu gihe gito, kandi bigafasha abarwayi gukoresha ibicuruzwa byateye imbere hakiri kare.
Kugira ngo wemererwe nkigikoresho cyo gutera imbere, ibisabwa bibiri byingenzi bigomba kuba byujujwe,
1, Imfashanyo mu kuvura neza cyangwa gusuzuma indwara zangiza cyangwa zangiza ubuzima.
2, Uzuza byibuze kimwe mubisabwa bikurikira,
A, Yerekana ikoranabuhanga rigezweho.
B, Nta bicuruzwa byemewe byemewe.
C, Gereranya nibicuruzwa byemewe byemewe, bifite ibyiza byingenzi.
D, Gukoresha ni inyungu zumurwayi.
Iri zina ntirisobanura gusa ko udushya twa Epiprobe mu ikoranabuhanga mu gutahura hakiri kare kanseri ya urothelia yamenyekanye n'abayobozi, ariko kandi yemeza akamaro gakomeye k’ubuvuzi n’agaciro gakomeye ka UCOM (ibimenyetso bya kanseri ku isi hose) mu kumenya kanseri y’inkari.Ibikoresho byo kumenya kanseri ya Urothelia nabyo bizinjira muburyo bwihuse bwo kwiyandikisha, gusaba no kwamamaza muri Amerika.
Igihe cyo kohereza: Jun-09-2023